Clinical Trial: Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan

U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755826) titled 'Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan' on Aug. 05.

Brief Summary: This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with repotrectinib. The study will describe how often side effects occur during treatment, with special attention to central nervous system disorders, interstitial lung disease, and fractures.

Study Start Date: Nov. 20, 2025

Study Type: OBSERVATIONAL

Condition: NTRK Fusion-positive Solid...